Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE

NCT04895982 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04895982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2021
Completion date
July 23, 2023
Enrollment
124 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection, covid19